Dedicated randomized clinical trials are therefore needed to test the clinical efficacy of conventional PCSK9 inhibitors or newly developed Lp(a) inhibitors [41, 42] in preventing AS progression. The gene discussed is PCSK9; the disease is aortic stenosis.